title: Response.
authors.affiliation: The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom (FS, DC, CP, DW). francesco.sclafani@rmh.nhs.uk.
authors.forename: Francesco
authors.initials: F
authors.lastname: Sclafani
authors.affiliation: The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom (FS, DC, CP, DW).
authors.forename: David
authors.initials: D
authors.lastname: Cunningham
authors.affiliation: The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom (FS, DC, CP, DW).
authors.forename: Clare
authors.initials: C
authors.lastname: Peckitt
authors.affiliation: The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom (FS, DC, CP, DW).
authors.forename: David
authors.initials: D
authors.lastname: Watkins
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D005260:Female; D006801:Humans; D008297:Male; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D017526:Receptor, IGF Type 1 / Q000378:metabolism*; D018631:ras Proteins / Q000235:genetics*
chemical_list: D011518:Proto-Oncogene Proteins; D066246:ErbB Receptors; D017526:Receptor, IGF Type 1; D018631:ras Proteins